- Price is above the Trend Line, keeping the weekly tape constructive.
- 4 accumulation markers appear in the recent smart-money tape.
SYNCOMF
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Syncom Formulations (India) Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
13.45 INR
2.5%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is 0.7% above the Trend Line and sits at 37.7% of its 52-week range. The latest completed week returned 2.5%, after a -5.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.
Setup score
29
out of 100
Latest Close
13.45 INR
7 Aug 2026
1W Return
2.5%
latest completed week
4W Return
-5.1%
short-term follow-through
12W Return
-2.5%
quarterly tape
Trend Breadth
11.5%
6 of 52 weeks active
Volume Ratio
1.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 42.82% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
2.5%
Latest completed week; four-week move -5.1%.
Indicator stack
6/31
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 42.82%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
15 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 0.7% above the Trend Line and sits at 37.7% of its 52-week range. The latest completed week returned 2.5%, after a -5.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1412-week average 0.24
12-week confirmation
Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.14Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
4 accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -5.1% over four weeks, -2.5% over 12 weeks, and -26.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year6
Trend breadth11.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.38Latest activity-pressure read.
Pressure change-151.8%Four-week change in activity pressure.
Leadership-6.69Latest relative-leadership reading.
RS change-156.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength75/100Blend of value, momentum, and quality. Underlying universe rank 26; rank 1 is best.
Value74/100Relative valuation strength. Underlying universe rank 27; rank 1 is best.
Quality79/100Profitability and accounting quality. Underlying universe rank 22; rank 1 is best.
Momentum14/100Medium-term price momentum. Underlying universe rank 87; rank 1 is best.
Growth65/100Revenue and earnings growth. Underlying universe rank 36; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework71/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 16.5x Price divided by trailing earnings.
- Price / sales
- 2.6x Market value relative to trailing revenue.
- EV / EBITDA
- 11.6x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 41.9% Gross profit retained from each unit of revenue.
- Operating margin
- 14.5% Operating profit retained from revenue.
- Free-cash-flow margin
- 9.5% Free cash flow generated from revenue.
- Return on invested capital
- 12.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 5.2% Latest one-year revenue growth.
- EPS growth
- 54.6% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 244.4% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 15 relevant articles.
0 positive · 15 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-28.5%Distance below the 52-week high.
13-week volatility3.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher12 of 2614 weeks finished lower.
Best week+20.0%Week of 10 Apr.
Worst week-7.1%Week of 27 Mar.
Latest week+2.5%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains8
Flat weeks0
Modest losses8
Sharp losses6
Recent vol3.2%13-week weekly-return volatility.
Base vol4.9%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew4.0% / -3.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank67 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape27/100
Trend, activity pressure, participation, and risk combine to a 27/100 tape read.
Indicator analysis49/100Latest 12-week confirmation: trend 6/12, activity pressure 10/12, relative leadership 2/12.
Activity pressure 0.14; No reversal markers Next-Week ExpectancyNegative 42.82%Next-week expectancy is negative with a 42.82% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors62/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 58; Small Cap Core rank 50 SVQF71/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 451.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 15 relevant articles.
Syncom Formulations MD Vijay Shankarlal Bankda resigns on Aug 11 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 13.45 INR | 2.5% | 13.35 INR | 15.35 INR | -0.38 | -6.69 | 7.6M | Off |
| 31 Jul 2026 | 13.12 INR | 0.2% | 13.34 INR | 15.32 INR | -0.07 | -8.88 | 3.7M | On |
| 24 Jul 2026 | 13.09 INR | -2.8% | 13.38 INR | 15.30 INR | 0.25 | -7.32 | 5.3M | On |
| 17 Jul 2026 | 13.47 INR | -5.0% | 13.43 INR | 15.27 INR | 0.53 | -7.38 | 6.7M | On |
| 10 Jul 2026 | 14.18 INR | -0.4% | 13.46 INR | 15.23 INR | 0.73 | -2.61 | 8.4M | On |
| 3 Jul 2026 | 14.24 INR | 2.5% | 13.49 INR | 15.19 INR | 0.72 | -2.96 | 1.3M | On |
| 26 Jun 2026 | 13.89 INR | -0.7% | 13.52 INR | 15.14 INR | 0.75 | -5.01 | 0 | On |
| 19 Jun 2026 | 13.99 INR | -2.0% | 13.58 INR | 15.10 INR | 1.02 | -4.68 | 1.5M | Off |
| 12 Jun 2026 | 14.27 INR | -1.5% | 13.64 INR | 15.06 INR | 1.10 | -1.72 | 1.5M | Off |
| 5 Jun 2026 | 14.49 INR | -3.5% | 13.71 INR | 15.02 INR | 1.14 | 0.05 | 1.4M | Off |
| 29 May 2026 | 15.01 INR | 4.7% | 13.77 INR | 14.98 INR | 1.32 | 2.18 | 38.9M | Off |
| 22 May 2026 | 14.34 INR | 3.9% | 13.82 INR | 14.92 INR | 1.13 | -3.84 | 8.4M | Off |
| 15 May 2026 | 13.80 INR | -5.9% | 13.89 INR | 14.87 INR | 1.11 | -7.67 | 9.4M | Off |
| 8 May 2026 | 14.67 INR | 6.8% | 13.98 INR | 14.82 INR | 1.18 | -4.35 | 12.4M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.